Q&A with Steve Strickland, Sensient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Steve Strickland, Sensient
Steve Strickland, general manager of Sensient Pharmaceutical Coating Systems, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 7, pp. 84

Q&A with Steve Strickland, general manager of Sensient Pharmaceutical Coating Systems

PharmTech:



What is the biggest industry challenge you're now facing?

Strickland:

A major challenge is maintaining continuous scientific innovation to meet the product demands of our customers. We are constantly looking for opportunities to expand our technical expertise and service either through internal development or acquisition.

I think that the consolidation within the pharmaceutical industry we serve will continue to play a role in our growth. Consolidation often brings personnel change, accompanied by shifts in the direction of research and development. We need to evolve along with our customers based on their changing needs.

PharmTech:

How do you stay abreast of new developments in the industry?

Strickland:

Our primary method of staying on top of industry developments is listening to our customers. Also, trade shows and trade publications are an excellent source of emerging industry trends, and we'll continue to rely on them.

PharmTech:

Do you see a new industry trend emerging?

Strickland:

Yes, the trend toward globalization of our industry continues to gain momentum. For example, the emergence of global markets, the multinational presence of pharmaceutical companies, and the location of manufacturing sites around the world demand an increased knowledge of the accompanying regulatory requirements.

PharmTech:

What is the most common demand your clients are currently making of you?

Strickland:

They demand high product quality. In an industry that is constantly under scrutiny, our customers demand excellence in the quality and performance of our products.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here